Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders. The company operates within the biotechnology and pharmaceuticals industries, with a primary emphasis on neurological and psychiatric conditions that have significant unmet medical needs. ACADIA’s core revenue driver is its approved CNS-focused pharmaceutical products, supported by ongoing research and development activities aimed at expanding indications and advancing new drug candidates.
The company’s primary commercial product is NUPLAZID® (pimavanserin), approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA primarily serves neurologists, psychiatrists, and institutional healthcare providers, positioning itself as a specialized CNS innovator. Founded in 1993, the company initially pursued broader neuroscience research before strategically narrowing its focus to CNS disorders, evolving into a commercial-stage biopharmaceutical company following regulatory approval of NUPLAZID in 2016.
Business Operations
ACADIA’s operations are organized around two principal activities: the commercialization of NUPLAZID® and the research and development of CNS-focused drug candidates. Revenue is predominantly generated from U.S. sales of NUPLAZID, with commercialization activities including medical affairs, sales, and post-marketing studies. Research and development efforts support both lifecycle management of existing products and the advancement of pipeline assets targeting neurological and psychiatric indications.
The company operates primarily in the United States, with additional international activities through licensing and collaboration arrangements. ACADIA controls proprietary small-molecule technologies and intellectual property related to serotonin receptor modulation. Its operations include wholly owned subsidiaries that support clinical development and commercialization, and the company has engaged in selective partnerships for international rights and regional commercialization outside the U.S.
Strategic Position & Investments
Strategically, ACADIA is focused on expanding its CNS franchise through both organic pipeline development and targeted external opportunities. Growth initiatives have included clinical programs to evaluate pimavanserin in additional neuropsychiatric indications, as well as investment in earlier-stage assets aimed at addressing conditions such as schizophrenia, Alzheimer’s disease psychosis, and other CNS disorders.
The company has made notable investments in pipeline expansion, including the acquisition of CerSci Therapeutics in 2021 to enhance its preclinical CNS research capabilities. ACADIA continues to allocate significant capital toward research and development, reflecting its strategy to build long-term value through innovation in CNS therapeutics. Its portfolio remains concentrated, with strategic emphasis on advancing differentiated mechanisms of action in neuroscience.
Geographic Footprint
ACADIA Pharmaceuticals is headquartered in San Diego, California, which serves as the center for its executive leadership, research, and corporate operations. The company’s commercial footprint is primarily concentrated in North America, where the majority of its revenue is generated through U.S. product sales.
Internationally, ACADIA maintains a limited but strategic presence through partnerships and licensing agreements, particularly in Europe and other select markets. While it does not operate large-scale manufacturing or sales organizations globally, its international influence is driven by regulatory filings, collaborative commercialization efforts, and clinical development activities conducted across multiple regions.
Leadership & Governance
ACADIA is led by an executive team with extensive experience in biopharmaceutical development, commercialization, and CNS-focused research. The leadership emphasizes a strategy centered on scientific rigor, disciplined capital allocation, and long-term value creation through innovation in neuroscience.
Key executives include:
- Catherine Owen Adams – Chief Executive Officer
- Mark C. Schneyer – Chief Financial Officer
- Saurabh Saha, MD, PhD – Chief Scientific Officer
- Elizabeth A. Santhanam – Chief Legal Officer
- Stephen R. Davis – Chief Business Officer
The company is governed by a board of directors responsible for oversight of strategy, risk management, and corporate governance, with a stated commitment to compliance, ethical conduct, and shareholder accountability.